Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

BACKGROUND: (177)LuPSMA is an effective treatment in metastatic castrate-resistant prostate cancer with trials adopting a standardised dose interval. Adjusting treatment intervals utilising early response biomarkers may improve patient outcomes. OBJECTIVE: This study evaluated progression-free survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Emmett, Louise, John, Nikeith, Pathmanandavel, Sarennya, Counter, William, Ayers, Maria, Sharma, Shikha, Agrawal, Shikha, Poole, Aron, Hovey, Elizabeth, Pranavan, Ganes, Gedye, Craig, Mallesara, Girish, Guminski, Alex, Lee, Adrian, Stockler, Martin R., Hickey, Adam, Eu, Peter, Joshua, Anthony M., Crumbaker, Megan, Nguyen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Advancing and Innovating in the Era of PSMA theranostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983078/
https://www.ncbi.nlm.nih.gov/pubmed/36872949
http://dx.doi.org/10.1177/17588359231156392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983078/
https://www.ncbi.nlm.nih.gov/pubmed/36872949
http://dx.doi.org/10.1177/17588359231156392

Ejemplares similares